In IPF, TNIK inhibitors (e.g., INS018_055/Rentosertib) target TRAF2-regulated fibrotic pathways, reducing myofibroblast differentiation and extracellular matrix deposition. This evidence concerns the gene TRAF2 and idiopathic pulmonary fibrosis.